Metastatic Lung Adenocarcinoma Treatment Market Outlook Report 2026-2030: Targeted Therapies Fuel Growth, with Revenues Reaching $5 Billion by 2030 [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Metastatic Lung Adenocarcinoma Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The metastatic lung adenocarcinoma treatment market has demonstrated robust growth, set to expand from $4.54 billion in 2025 to $4.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.9%. Historical market progression has been driven by increasing lung cancer prevalence, enhanced diagnostic techniques, and the adoption of therapies such as platinum chemotherapy. Between 2021 and 2026, notable advancements include the integration of EGFR inhibitors and radiation therapy. Looking ahead, the market is positioned to grow to $7.21 billion by 2030 at a CAGR of 9.6%. The forecast period is marked by a trend towards precision medicine within lung adenocarcinoma treatment, offering targeted solutions that harness data-driven insights. Expansion in ALK and ROS1 inhibitors, the rise of immunotherapy combinations,
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- This Healthcare Stock Barely Flinches During Market Sell-Offs [Yahoo! Finance]Yahoo! Finance
- JNJ Q1 MedTech Preview: Key Drivers and China Headwinds to Watch [Yahoo! Finance]Yahoo! Finance
- Factbox-Global pharma companies that have publicly announced Trump drug pricing agreements [Yahoo! Finance]Yahoo! Finance
- Why Johnson & Johnson (JNJ) Is One of the Best Pharma Stocks to Invest in Now [Yahoo! Finance]Yahoo! Finance
- JNJ Stock's 60% Breakout: Why Wall Street is Torn [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/18/26 - Form 13F-HR/A
- 3/18/26 - Form 13F-HR/A
- JNJ's page on the SEC website